Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
04:16pm, Tuesday, 10'th Mar 2026
Brazilian drugmaker EMS is open to fresh acquisitions to expand internationally after inking a major deal to buy Sanofi's Brazil-based generic drugmaker Medley, and is gearing up to launch its own
Sanofi (NASDAQ:SNY) Hits New 1-Year Low – Here’s Why
01:32am, Sunday, 08'th Mar 2026
Sanofi (NASDAQ: SNY - Get Free Report) shares hit a new 52-week low during mid-day trading on Friday. The company traded as low as $44.01 and last traded at $44.01, with a volume of 93153 shares. The
Need Growing EPS And Dividends? Prescribe Sanofi
08:00am, Friday, 06'th Mar 2026
Sanofi is deeply undervalued, trading at a 29% discount to a $65 fair value estimate, with a forward P/E of 9.2 versus a 10-year average of 13. Robust growth is driven by blockbuster drugs like Dupixe
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
03:16am, Thursday, 05'th Mar 2026
Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
Press Release: Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report
12:30pm, Wednesday, 04'th Mar 2026
Filing of an amendment to the French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
06:13pm, Tuesday, 03'rd Mar 2026
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharm
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
11:01am, Tuesday, 03'rd Mar 2026
SNY wins Japan orphan drug tag for Waylirz in IgG4-RD and adds regulatory perks as the BTK inhibitor advances in late-stage studies.
American Century Companies Inc. Acquires 379,784 Shares of Sanofi $SNY
03:07am, Tuesday, 03'rd Mar 2026
American Century Companies Inc. raised its holdings in shares of Sanofi (NASDAQ: SNY) by 19.4% during the undefined quarter, according to the company in its most recent filing with the Securities and
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
10:10am, Monday, 02'nd Mar 2026
Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
09:40am, Monday, 02'nd Mar 2026
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Becker Capital Management Inc. Sells 45,719 Shares of Sanofi $SNY
05:05am, Monday, 02'nd Mar 2026
Becker Capital Management Inc. cut its holdings in shares of Sanofi (NASDAQ: SNY) by 8.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Excha
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
01:00am, Monday, 02'nd Mar 2026
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi
Citigroup Inc. Sells 226,396 Shares of Sanofi $SNY
03:51am, Sunday, 01'st Mar 2026
Citigroup Inc. reduced its holdings in shares of Sanofi (NASDAQ: SNY) by 48.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The instit
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3
